These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 26041408)

  • 1. Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.
    Devineni D; Polidori D
    Clin Pharmacokinet; 2015 Oct; 54(10):1027-41. PubMed ID: 26041408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.
    Devineni D; Curtin CR; Polidori D; Gutierrez MJ; Murphy J; Rusch S; Rothenberg PL
    J Clin Pharmacol; 2013 Jun; 53(6):601-10. PubMed ID: 23670707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
    Sha S; Devineni D; Ghosh A; Polidori D; Hompesch M; Arnolds S; Morrow L; Spitzer H; Demarest K; Rothenberg P
    PLoS One; 2014; 9(9):e110069. PubMed ID: 25268802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
    Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
    Devineni D; Vaccaro N; Murphy J; Curtin C; Mamidi RN; Weiner S; Wang SS; Ariyawansa J; Stieltjes H; Wajs E; Di Prospero NA; Rothenberg P
    Int J Clin Pharmacol Ther; 2015 Feb; 53(2):115-28. PubMed ID: 25407255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Rosenthal N; Meininger G; Ways K; Polidori D; Desai M; Qiu R; Alba M; Vercruysse F; Balis D; Shaw W; Edwards R; Bull S; Di Prospero N; Sha S; Rothenberg P; Canovatchel W; Demarest K
    Ann N Y Acad Sci; 2015 Nov; 1358():28-43. PubMed ID: 26305874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.
    Kasichayanula S; Liu X; Lacreta F; Griffen SC; Boulton DW
    Clin Pharmacokinet; 2014 Jan; 53(1):17-27. PubMed ID: 24105299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants.
    Devineni D; Manitpisitkul P; Murphy J; Stieltjes H; Ariyawansa J; Di Prospero NA; Rothenberg P
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):279-86. PubMed ID: 27136908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.
    Devineni D; Vaccaro N; Polidori D; Stieltjes H; Wajs E
    Int J Clin Pharmacol Ther; 2015 Feb; 53(2):129-38. PubMed ID: 25500487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
    Devineni D; Vaccaro N; Polidori D; Rusch S; Wajs E
    Clin Ther; 2014 May; 36(5):698-710. PubMed ID: 24726680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin.
    de Winter W; Dunne A; de Trixhe XW; Devineni D; Hsu CH; Pinheiro J; Polidori D
    Br J Clin Pharmacol; 2017 May; 83(5):1072-1081. PubMed ID: 28138980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules.
    Mori K; Saito R; Nakamaru Y; Shimizu M; Yamazaki H
    Biopharm Drug Dispos; 2016 Nov; 37(8):491-506. PubMed ID: 27604638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
    Sha S; Devineni D; Ghosh A; Polidori D; Hompesch M; Arnolds S; Morrow L; Spitzer H; Demarest K; Rothenberg P
    PLoS One; 2014; 9(8):e105638. PubMed ID: 25166023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
    Iijima H; Kifuji T; Maruyama N; Inagaki N
    Adv Ther; 2015 Aug; 32(8):768-82. PubMed ID: 26280756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants.
    Devineni D; Polidori D; Curtin C; Stieltjes H; Tian H; Wajs E
    Clin Ther; 2016 Jan; 38(1):89-98.e1. PubMed ID: 26687552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes.
    Tamborlane WV; Polidori D; Argenti D; Di Prospero NA
    Pediatr Diabetes; 2018 Jun; 19(4):649-655. PubMed ID: 29271103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects.
    Sha S; Devineni D; Ghosh A; Polidori D; Chien S; Wexler D; Shalayda K; Demarest K; Rothenberg P
    Diabetes Obes Metab; 2011 Jul; 13(7):669-72. PubMed ID: 21457428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans.
    Francke S; Mamidi RN; Solanki B; Scheers E; Jadwin A; Favis R; Devineni D
    J Clin Pharmacol; 2015 Sep; 55(9):1061-72. PubMed ID: 25827774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma Pharmacokinetic Determination of Canagliflozin and Its Metabolites in a Type 2 Diabetic Rat Model by UPLC-MS/MS.
    Dong ST; Niu HM; Wu Y; Jiang JL; Li Y; Jiang KY; Wang X; Zhang MF; Han MF; Meng SN
    Molecules; 2018 May; 23(5):. PubMed ID: 29783787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Scheen AJ
    Clin Pharmacokinet; 2015 Jul; 54(7):691-708. PubMed ID: 25805666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.